Clustering of 37 circulating biomarkers by exploratory factor analysis in patients following complicated acute myocardial infarction

International Journal of Cardiology

Volumn 166, Issue 3, 2013, Pages 729-735

  Manhenke, Cord ^a,b   Ørn, Stein ^a,b   Von Haehling, Stephan ^c   Wollert, Kai C ^d   Ueland, Thor ^e   Aukrust, Pål ^e   Voors, Adriaan A ^f   Squire, Iain ^g,h   Zannad, Faiez ⁱ   Anker, Stefan D ^c,j   Dickstein, Kenneth ^a,b  

^a UNIVERSITY OF BERGEN   (Norway)

^b STAVANGER UNIVERSITY HOSPITAL   (Norway)

^c CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^d HANNOVER MEDICAL SCHOOL   (Germany)

^e UNIVERSITY OF OSLO   (Norway)

^f UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^g UNIVERSITY OF LEICESTER   (United Kingdom)

^h GLENFIELD HOSPITAL   (United Kingdom)

ⁱ Ctr Hospitalier Univ de Nancy   (France)

^j IRCCS SAN RAFFAELE PISANA   (Italy)

more..

Author keywords

Biomarkers exploratory factor analysis; Myocardial infarction; Prognosis

Indexed keywords

ALDOSTERONE; AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; AMINO TERMINAL TELOPEPTIDE; C REACTIVE PROTEIN; CD40 LIGAND; CHROMOGRANIN A; COPEPTIN; ERYTHROPOIETIN; FERRITIN; GELATINASE B; GROWTH DIFFERENTIATION FACTOR 15; INTERLEUKIN 10; INTERLEUKIN 18; INTERLEUKIN 6; INTERSTITIAL COLLAGENASE; IRON; MONOCYTE CHEMOTACTIC PROTEIN 1; N(G),N(G) DIMETHYLARGININE; NORADRENALIN; OSTEOPROTEGERIN; PLACENTAL GROWTH FACTOR; PROADRENOMEDULLIN; PROCOLLAGEN TYPE 3 AMINOPROPEPTIDE; TISSUE INHIBITOR OF METALLOPROTEINASE; TRANSFERRIN; TRANSFERRIN RECEPTOR; TUMOR NECROSIS FACTOR RECEPTOR; URIC ACID; VASCULOTROPIN; BIOLOGICAL MARKER;

ACUTE HEART INFARCTION; ADULT; AGE; ARTICLE; CARDIOVASCULAR MORTALITY; CAUSE OF DEATH; CONTROLLED STUDY; EXPLORATORY FACTOR ANALYSIS; FACTORIAL ANALYSIS; FIBRINOLYTIC THERAPY; GLOMERULUS FILTRATION RATE; HEART ATRIUM FIBRILLATION; HEART INFARCTION; HEART LEFT VENTRICLE FAILURE; HEART REINFARCTION; HUMAN; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; AGED; BLOOD; CLINICAL TRIAL; CLUSTER ANALYSIS; FEMALE; FOLLOW UP; MALE; MIDDLE AGED; MULTICENTER STUDY; MYOCARDIAL INFARCTION; RANDOMIZED CONTROLLED TRIAL; CONTROLLED CLINICAL TRIAL;

AGED; BIOLOGICAL MARKERS; CLUSTER ANALYSIS; FACTOR ANALYSIS, STATISTICAL; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION;

EID: 84893444024     PISSN: 01675273     EISSN: 18741754     Source Type: Journal    
DOI: 10.1016/j.ijcard.2011.11.089     Document Type: Article

References (32)

1. Voors AA, von Haehling S, Anker SD, et al. C-terminal provasopressin (copeptin) is a strong prognostic marker in patients with heart failure after an acute myocardial infarction: results from the OPTIMAAL study. Eur Heart J 2009; 30: 1187-94.
2. Estensen ME, Hognestad A, Syversen U, et al. Prognostic value of plasma chromo-granin A levels in patients with complicated myocardial infarction. Am Heart J 2006; 152(927) e1-6.
3. Ueland T, Kjekshus J, Froland SS, et al. Plasma levels of soluble tumor necrosis factor receptor type I during the acute phase following complicated myocardial infarction predicts survival in high-risk patients. J Am Coll Cardiol 2005; 46: 2018-21.
4. Ueland T, Aukrust P, Yndestad A, et al. Soluble CD40 ligand in acute and chronic heart failure. Eur Heart J 2005; 26: 1101-7.
5. Squire IB, Orn S, Ng LL, et al. Plasma natriuretic peptides up to 2 years after acute myocardial infarction and relation to prognosis: an OPTIMAAL substudy. J Card Fail 2005; 11: 492-7.
6. Ueland T, Jemtland R, Godang K, et al. Prognostic value of osteoprotegerin in heart failure after acute myocardial infarction. J Am Coll Cardiol 2004; 44: 1970-6.
7. Orn S, Manhenke C, Squire IB, Ng L, Anand I, Dickstein K. Plasma MMP-2, MMP-9 and N-BNP in long-term survivors following complicated myocardial infarction: relation to cardiac magnetic resonance imaging measures of left ventricular structure and function. J Card Fail 2007; 13: 843-9.
8. Belonje AM, Westenbrink BD, Voors AA, et al. Erythropoietin levels in heart failure after an acute myocardial infarction: determinants, prognostic value, and the effects of captopril versus losartan. Am Heart J 2009; 157: 91-6.
9. Manhenke C, Orn S, Squire I, et al. The prognostic value of circulating markers of collagen turnover after acute myocardial infarction. Int J Cardiol 2011; 150: 277-82.
10. Anker SD, Voors A, Okonko D, et al. Prevalence, incidence, and prognostic value of anaemia in patients after an acute myocardial infarction: data from the OPTIMAAL trial. Eur Heart J 2009; 30: 1331-9.
11. Braunwald E. Biomarkers in heart failure. N Engl J Med 2008; 358: 2148-59.
12. Chan D, Ng L. Biomarkers in acute myocardial infarction. BMC Med 2010; 8: 34.
13. Knafl GJ, Grey M. Factor analysis model evaluation through likelihood cross-validation. Stat Methods Med Res 2007; 16: 77-102.
14. Field AP Discovering statistics using SPSS. 3rd ed. London: SAGE; 2009.
15. Dickstein K, Kjekshus J. Comparison of the effects of losartan and captopril on mortality in patients after acute myocardial infarction: the OPTIMAAL trial design. Optimal therapy in myocardial infarction with the angiotensin II antagonist losartan. Am J Cardiol 1999; 83: 477-81.
16. Dickstein K, Kjekshus J. Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: the OPTIMAAL randomised trial. Optimal trial in myocardial infarction with angiotensin II antagonist losartan. Lancet 2002; 360: 752-60.
17. Leyva F, Anker S, Swan JW, et al. Serum uric acid as an index of impaired oxidative metabolism in chronic heart failure. Eur Heart J 1997; 18: 858-65.
18. Tziakas DN, Chalikias GK, Kaski JC, et al. Inflammatory and anti-inflammatory variable clusters and risk prediction in acute coronary syndrome patients: a factor analysis approach. Atherosclerosis 2007; 193: 196-203.
19. Hutcheson G, Sofroniou N. The multivariate social scientists: introductory statistics using generalized linear models. London: SAGE; 1999.
20. Rabe-Hesketh S, Skrondal A. Classical latent variable models for medical research. Stat Methods Med Res 2008; 17: 5-32.
21. Brugger-Andersen T, Aarsetoy H, Grundt H, Staines H, Nilsen DW. The long-term prognostic value of multiple biomarkers following a myocardial infarction. Thromb Res 2008; 123: 60-6.
22. Guadagnoli E, Velicer W. Relation of sample size to the stability of component patterns. Psychol Bull 1988; 103: 265-75.
23. Adlbrecht C, Hulsmann M, Strunk G, et al. Prognostic value of plasma midregional pro-adrenomedullin and C-terminal-pro-endothelin-1 in chronic heart failure outpatients. Eur J Heart Fail 2009; 11: 361-6.
24. Khan SQ, O'Brien RJ, Struck J, et al. Prognostic value of midregional pro-adrenomedullin in patients with acute myocardial infarction: the LAMP (Leicester Acute Myocardial Infarction Peptide) study. J Am Coll Cardiol 2007; 49: 1525-32.
25. Khan S, Dhillon O, Struck J, et al. C-terminal pro-endothelin-1 offers additional prognostic information in patients after acute myocardial infarction: Leicester Acute Myocardial Infarction Peptide (LAMP) study. Am Heart J 2007; 154: 736-42.
26. Jansson AM, Rosjo H, Omland T, et al. Prognostic value of circulating chromogranin A levels in acute coronary syndromes. Eur Heart J 2009; 30: 25-32.
27. Uusimaa P, Risteli J, Niemela M, et al. Collagen scar formation after acute myocardial infarction: relationships to infarct size, left ventricular function, and coronary artery patency. Circulation 1997; 96: 2565-72.
28. Cheng TH, Lin JW, Chao HH, et al. Uric acid activates extracellular signal-regulated kinases and thereafter endothelin-1 expression in rat cardiac fibroblasts. Int J Cardiol 2010; 139: 42-9.
29. Jugdutt BI Ventricular remodeling after infarction and the extracellular collagen matrix: when is enough enough? Circulation 2003; 108: 1395-403.
30. Kempf T, Horn-Wichmann R, Brabant G, et al. Circulating concentrations of growth-differentiation factor 15 in apparently healthy elderly individuals and patients with chronic heart failure as assessed by a new immunoradiometric sandwich assay. Clin Chem 2007; 53: 284-91.
31. Wollert KC, Kempf T, Peter T, et al. Prognostic value of growth-differentiation factor-15 in patients with non-ST-elevation acute coronary syndrome. Circulation 2007; 115: 962-71.
32. Anand IS, Kempf T, Rector TS, et al. Serial measurement of growth-differentiation factor-15 in heart failure: relation to disease severity and prognosis in the Valsartan Heart Failure Trial. Circulation 2010; 122: 1387-95.